07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Immune Pharmaceuticals deal

Immune will spin out a new company focused on pain and neurology. The newco will own IP for AmiKet and other pain and neurology assets. Healthcare investor Novel Pain Therapeutics LLC (New York, N.Y.)...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

Hebrew University of Jerusalem, Immune Pharmaceuticals deal

Yissum, the tech transfer arm of the university, granted Immune exclusive, worldwide rights to patents covering a topical nano-formulated version of AmiKet to treat neuropathic pain. Yissum is eligible to receive up to $4.5...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

EpiCept, Immune Pharmaceuticals deal

The companies announced they will merge in a stock deal. After the deal, which is expected to close next quarter, former EpiCept shareholders will own 22.5% of the combined company, which will be named Immune...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

EpiCept, Meda sales and marketing update

EpiCept made several moves to save cash and extend its projected operations into 4Q12. EpiCept will receive $2.6 million in cash from Meda in exchange for relinquishing future milestones and royalties under a 2010 deal...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

AmiKet regulatory update

EpiCept said EMA's CHMP issued formal scientific advice on the development of AmiKet to treat chemotherapy-induced peripheral neuropathic pain (CIPN). CHMP recommended EpiCept include in an MAA a single, 12-week, 4-arm, factorial-designed trial in CIPN...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Clinical News

AmiKet regulatory update

FDA granted Fast Track designation for EpiCept's AmiKet to treat neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) in patients previously treated with taxane-based chemotherapy. EpiCept plans to begin a Phase III trial of AmiKet...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

EpiCept neurology news

EpiCept engaged SunTrust Robinson Humphrey to advise on maximizing the commercial value of AmiKet, a topical cream containing amitriptyline and ketamine. EpiCept said it is in partnering discussions for AmiKet and plans to begin...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Clinical News

EpiCept NP-1: Additional Phase IIb data

A double-blind, U.S. Phase IIb trial in >460 patients with painful CPN for at least 28 days following chemotherapy showed that twice-daily 4 mL topical EpiCept NP-1 for 6 weeks met the primary endpoint of...
08:00 , Feb 14, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Gilead Sciences Inc. (NASDAQ:GILD) lost $0.40 to $38.39 last week after resubmitting an NDA to FDA for a fixed-dose combination of rilpivirine and Truvada emtricitabine/tenofovir to treat HIV infection. Last month, the agency refused to...
00:54 , Feb 8, 2011 |  BC Extra  |  Clinical News

EpiCept gains on EpiCept-NP1 data

EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT) gained $0.10 (13%) to $0.85 on Monday after the company said EpiCept NP-1 met the primary endpoint in a Phase IIb trial to treat chemotherapy-induced peripheral neuropathy (CPN). The topical cream...